DMID 21-0041; Influenza CVD 59000
NCT05666245 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 34
Last updated 2025-08-26
Summary
The primary objective of EMIT-2 is to use a randomized controlled trial (RCT) design to implement interventions which are known to reduce inhalation (airborne) transmission, so that the contribution of transmission by route of aerosols for influenza may be identified.
Conditions
Interventions
- BEHAVIORAL
-
Personal Protective Equipment (PPE) - Under High Air Hygiene
Intervention Recipients (IRs) will be required to wear a lightweight plastic face shield, comply with hand hygiene (i.e., using a hand sanitization product every 15 minutes, plus periodic hand washing with soap and water), and avoid face touching during each planned exposure event. The face shield may only be removed after leaving the exposure room to go to the bathroom, for other short comfort breaks, and at mealtimes. In these instances, hand hygiene will be used after removing or replacing the face shield; and Donors will not be present. Hand washing with soap and water will be required before meals. IR will be separated from Donors by more than 6 feet during meals. The exposure room will be supervised by a trained member of the study staff who will monitor to ensure that Intervention Recipients wear the face shield continuously, are separated from Donors at meals, and do not touch their faces. High air hygiene is achieved by filtration and/or use of germicidal UV-C.
- BEHAVIORAL
-
No Intervention - Under High Air Hygiene
No intervention High air hygiene is achieved by filtration and/or use of germicidal UV-C.
- BEHAVIORAL
-
Personal Protective Equipment (PPE) - Under Low Air Hygiene
Intervention Recipients (IRs) will be required to wear a lightweight plastic face shield, comply with hand hygiene (i.e., using a hand sanitization product every 15 minutes, plus periodic hand washing with soap and water), and avoid face touching during each planned exposure event. The face shield may only be removed after leaving the exposure room to go to the bathroom, for other short comfort breaks, and at mealtimes. In these instances, hand hygiene will be used after removing or replacing the face shield; and Donors will not be present. Hand washing with soap and water will be required before meals. IR will be separated from Donors by more than 6 feet during meals. The exposure room will be supervised by a trained member of the study staff who will monitor to ensure that Intervention Recipients wear the face shield continuously, are separated from Donors at meals, and do not touch their faces. Low air hygiene is achieved with minimal ventilation.
- BEHAVIORAL
-
No Intervention - Under Low Air Hygiene
No intervention Low air hygiene is achieved with minimal ventilation.
Sponsors & Collaborators
-
University of Maryland, College Park
collaborator OTHER -
National Institute of Allergy and Infectious Diseases (NIAID)
collaborator NIH -
University of Maryland, Baltimore
lead OTHER
Study Design
- Allocation
- RANDOMIZED
- Purpose
- OTHER
- Masking
- NONE
- Model
- FACTORIAL
Eligibility
- Min Age
- 18 Years
- Max Age
- 59 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2023-02-20
- Primary Completion
- 2024-04-17
- Completion
- 2024-04-17
Countries
- United States
Study Locations
More Related Trials
-
A Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Combined Modified RNA Vaccine Candidate Against COVID-19 and Influenza.
NCT06178991 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy Study of an Investigational Influenza Vaccine (Vero Cell Derived) to Prevent Culture Confirmed Influenza Infection (CCII)
NCT00566345 ·Status: COMPLETED ·Phase: PHASE3
-
Evaluating Modes of Influenza Transmission Between Humans
NCT01150149 ·Status: WITHDRAWN ·Phase: NA
-
Influenza A H3N2 Human Challenge Study in Healthy Adult Volunteers
NCT02594189 ·Status: COMPLETED ·Phase: PHASE1
-
Study of Immune Responses in Healthy Adults Receiving Live Influenza Virus Vaccines
NCT01674205 ·Status: COMPLETED ·Phase: PHASE1
-
The Safety and Immunogenicity Evaluation of Live Attenuated Influenza Vaccine
NCT05056519 ·Status: UNKNOWN ·Phase: PHASE1
-
Study to Evaluate the Safety of a Bivalent Vaccine of New 6:2 Influenza Virus Reassortants in Healthy Adults
NCT00192127 ·Status: COMPLETED ·Phase: PHASE3
-
Establishing a Controlled Human Infection Model for Influenza H3N2 as a Foundation for Pandemic Preparedness
NCT07305207 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1
-
Immunogenicity, Safety and Tolerability of Prepandemic Influenza and Seasonal Influenza Vaccine in Adult Subjects
NCT00481065 ·Status: COMPLETED ·Phase: PHASE2
-
Trial to Demonstrate Equivalent Immunogenicity of CAIV-T and FLUMIST in Healthy Participants
NCT00192335 ·Status: COMPLETED ·Phase: PHASE3
-
Safety and Immunogenicity of Two Doses of H5N1 Influenza Vaccine in Healthy Adults
NCT01776541 ·Status: COMPLETED ·Phase: PHASE2
-
Safety, Tolerability, Efficacy and Immunogenicity of an Influenza A Vaccine (FP-01.1) in Healthy Volunteers Following Virus Challenge
NCT02071329 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
The Safety and Immunogenicity Evaluation of Live Attenuated Influenza Vaccine
NCT05284851 ·Status: UNKNOWN ·Phase: PHASE2
-
Evaluation of Influenza-Specific Immune Responses in Children and Adults During the 2010-2011 Influenza Season in the U.S.
NCT01262079 ·Status: COMPLETED
-
Safety and Immunogenicity of Two Doses of H5N1 Influenza Vaccine in Elderly Subjects
NCT01766921 ·Status: COMPLETED ·Phase: PHASE2
-
Immunogenicity Study of an Inactivated Influenza Vaccine (Split Virus, Vero Cell Derived) to Prevent Culture Confirmed Influenza Infection
NCT00800605 ·Status: COMPLETED ·Phase: PHASE3
-
Systems Biology of Flu Vaccine in Healthy Adults With and Without the Use of Antibiotics
NCT02154061 ·Status: COMPLETED ·Phase: NA
-
2009 H1N1 Pandemic and Seasonal Influenza in SCI/D: Infection Control Strategies
NCT01270685 ·Status: WITHDRAWN
-
Revealing Protective Immunity to Influenza Using Systems Immunology
NCT06501963 ·Status: COMPLETED ·Phase: PHASE4
-
Study of the Safety and Immunogenicity of an Influenza Vaccine Administered to Healthy Adults
NCT00264576 ·Status: COMPLETED ·Phase: PHASE2
-
Evaluating Immune Response to Seasonal FluMist in Healthy Adults
NCT01673425 ·Status: TERMINATED ·Phase: NA
-
Evaluating the Safety and Immune Response to an H5N1 Influenza Vaccine in People Who Have Previously Received an H5N1 or H7N3 Influenza Vaccine and in People Who Have Never Received a Live Attenuated Influenza Vaccine
NCT01443663 ·Status: COMPLETED ·Phase: PHASE1
-
Influenza Challenge Study in Healthy Volunteers
NCT02746211 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Comparing the Efficacy and Safety of High-Titer Versus Low-Titer Anti-Influenza Immune Plasma for the Treatment of Severe Influenza A
NCT02572817 ·Status: COMPLETED ·Phase: PHASE3
-
Inactivated Influenza Via Jet Injection
NCT02290691 ·Status: COMPLETED ·Phase: PHASE4